Stammdaten
Oruka Therapeutics, Inc. ist ein Biotechnologie-Unternehmen, das sich auf die Entwicklung neuartiger monoklonaler Antikörper-Therapeutika für PsO und andere I&I-Indikationen konzentriert. Seine Pipeline umfasst ORKA-001 und ORKA-002. Das Unternehmen hat seinen Hauptsitz in Menlo Park, CA. KI
Unternehmen & Branche
| Name | Oruka Therapeutics, Inc. |
|---|---|
| Ticker | ORKA |
| CIK | 0000907654 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 687604108 |
|---|---|
| ISIN | US6876041087 |
| Typ | Common Stock |
| Marktkapitalisierung | 4,49 Mrd. USD |
| Beta | -0,30 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 855 OAK GROVE AVE. SUITE 100, 94025 MENLO PARK, CA |
| Telefon | 650-606-7910 |
| EIN (IRS) | 36-3855489 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Non-accelerated filer, Smaller reporting company |
| Frühere Namen | ARCA biopharma, Inc. (bis 2024) NUVELO INC (bis 2009) HYSEQ INC (bis 2003) |
Bewertung
| KBV (P/B) | 9,51 vs. 7,28 (2021) ▲ |
|---|---|
| FCF-Rendite | -2,0 % vs. -5,1 % (2021) ▲ |
Qualität & Bilanz
| ROIC | -22,2 % vs. -37,5 % (2021) ▲ |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 7,28 | 9,83 | 7,99 | 3,13 | 9,23 | |
| FCF-Rendite | -5,1 % | -2,7 % | -1,7 % | -6,0 % | -2,0 % | |
| Qualität & Bilanz | ||||||
| ROIC | -37,5 % | -23,6 % | -14,3 % | -22,2 % | -23,8 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ORKA
Oruka Therapeutics, Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
64,8
58 neu, 64 erhöht, 957,1M $ netto
Aktivist
18,3
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 75.34 | +19.7 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 47.64 | +89.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 87.55 | EMA50: 78.63 | |
| MACD-Histogramm | Bärisch | 10 % | -0.460 | Bearisch | |
| RSI(14) | Neutral | 10 % | 57.5 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 61.0 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 33.8 | +DI: 24.6 / −DI: 14.7 | |
| Z-Score(60) | Neutral | 5 % | 1.26 | In Range | |
| 52W-Position | Bullisch | 5 % | 93.9 % | Hoch 95.17 / Tief 13.05 | |
| Bollinger(20,2σ) | Neutral | 5 % | 57.5 % | Upper 96.89 / Mid 89.03 / Lower 81.16 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.6336 | R²=0.70 / annualisiert +216.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -300 | 87,25 | -26.175,99 | -0,5% | |
| 2026-07-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -3.803 | 86,68 | -329.630,35 | -6,6% | |
| 2026-07-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.497 | 85,86 | -214.385,43 | -4,3% | |
| 2026-07-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -400 | 84,37 | -33.746,00 | -0,7% | |
| 2026-07-13 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -300 | 85,63 | -25.689,99 | -0,5% | |
| 2026-07-13 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -5.656 | 84,90 | -480.201,19 | -9,6% | |
| 2026-07-13 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -3.743 | 84,26 | -315.369,09 | -6,3% | |
| 2026-07-13 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -300 | 83,07 | -24.919,95 | -0,5% | |
| 2026-07-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2.237 | 93,85 | -209.932,83 | -4,2% | |
| 2026-07-01 | Fairmount Funds Management LLC | Director, 10% Owner | Open Market Sale | -3.553.410 | 84,43 | -300.014.406,30 | -5999,6% | |
| 2026-07-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2.263 | 94,75 | -214.409,75 | -4,3% | |
| 2026-07-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -500 | 95,47 | -47.736,00 | -1,0% | |
| 2026-06-22 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -888 | 80,01 | -71.048,88 | -1,4% | |
| 2026-06-22 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -699 | 82,15 | -57.419,36 | -1,1% | |
| 2026-06-15 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -395 | 69,69 | -27.527,55 | -0,6% | |
| 2026-06-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -5.064 | 69,42 | -351.547,44 | -7,0% | |
| 2026-06-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1.636 | 68,38 | -111.876,06 | -2,2% | |
| 2026-06-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -947 | 69,69 | -65.996,43 | -1,3% | |
| 2026-06-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -300 | 70,62 | -21.186,99 | -0,4% | |
| 2026-06-15 | Klein Lawrence Otto | Director, Officer, Chief Executive Officer | Open Market Sale | -1.729 | 69,69 | -120.494,01 | -2,4% | |
| 2026-06-15 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -600 | 69,69 | -41.814,00 | -0,8% | |
| 2026-06-15 | Quinlan Paul T | Officer, General Counsel | Open Market Sale | -733 | 69,69 | -51.082,77 | -1,0% | |
| 2026-06-12 | Dambkowski Carl | Director | Open Market Sale | -12.583 | 70,11 | -882.181,55 | -17,6% | |
| 2026-06-12 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -4.340 | 69,85 | -303.154,21 | -6,1% | |
| 2026-06-12 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -3.260 | 70,34 | -229.305,79 | -4,6% | |
| 2026-06-12 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -1.859 | 68,34 | -127.047,59 | -2,5% | |
| 2026-06-11 | Dambkowski Carl | Director | Open Market Sale | -22.417 | 70,13 | -1.572.200,60 | -31,4% | |
| 2026-05-21 | Dambkowski Carl | Director | Open Market Sale | -38.318 | 58,43 | -2.238.794,29 | -44,8% | |
| 2026-05-21 | Dambkowski Carl | Director | Open Market Sale | -13.235 | 59,97 | -793.661,92 | -15,9% | |
| 2026-05-21 | Dambkowski Carl | Director | Open Market Sale | -53.447 | 59,10 | -3.158.910,11 | -63,2% | |
| 2026-05-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.100 | 62,42 | -131.088,30 | -2,6% | |
| 2026-05-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -100 | 63,52 | -6.352,00 | -0,1% | |
| 2026-05-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -4.800 | 61,56 | -295.494,72 | -5,9% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -100 | 68,48 | -6.848,00 | -0,1% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2.200 | 62,58 | -137.685,46 | -2,8% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -1.800 | 64,15 | -115.467,84 | -2,3% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -400 | 66,06 | -26.422,00 | -0,5% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -300 | 65,10 | -19.530,00 | -0,4% | |
| 2026-05-01 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -200 | 67,16 | -13.431,00 | -0,3% | |
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.273 | 66,56 | -151.300,65 | -3,0% | |
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -4.227 | 65,73 | -277.836,91 | -5,6% | |
| 2026-04-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -500 | 67,38 | -33.692,00 | -0,7% | |
| 2026-03-16 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -600 | 41,30 | -24.780,00 | -0,5% | |
| 2026-03-16 | Agarwal Arjun | Officer, Senior Vice President, Finance | Open Market Sale | -395 | 41,30 | -16.313,50 | -0,3% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.921 | 40,11 | -117.158,68 | -2,3% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.902 | 41,20 | -119.568,78 | -2,4% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1.177 | 41,94 | -49.358,79 | -1,0% | |
| 2026-03-16 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -641 | 41,30 | -26.473,30 | -0,5% | |
| 2026-03-16 | Klein Lawrence Otto | Director, Officer, Chief Executive Officer | Open Market Sale | -1.729 | 41,30 | -71.407,70 | -1,4% | |
| 2026-03-16 | Quinlan Paul T | Officer, General Counsel | Open Market Sale | -733 | 41,30 | -30.272,90 | -0,6% | |
| 2026-03-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2.675 | 33,81 | -90.435,60 | -1,8% | |
| 2026-03-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -2.325 | 33,28 | -77.386,00 | -1,5% | |
| 2026-02-17 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -6.064 | 32,30 | -195.872,66 | -3,9% | |
| 2026-02-17 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -936 | 32,78 | -30.686,01 | -0,6% | |
| 2026-01-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -4.381 | 31,56 | -138.275,75 | -2,8% | |
| 2026-01-15 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -2.619 | 32,24 | -84.428,70 | -1,7% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -3.144 | 29,08 | -91.431,92 | -1,8% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -8.748 | 28,17 | -246.396,17 | -4,9% | |
| 2026-01-02 | Sandler Laura Lee | Officer, Chief Operating Officer | Open Market Sale | -1.108 | 29,75 | -32.966,99 | -0,7% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1.492 | 30,70 | -45.806,04 | -0,9% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -3.080 | 31,58 | -97.263,32 | -1,9% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -1.787 | 29,62 | -52.934,51 | -1,1% | |
| 2025-12-19 | Goncalves Joana | Officer, Chief Medical Officer | Open Market Sale | -641 | 28,53 | -18.289,14 | -0,4% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 7.431.403 | 0 | 7.431.403 | 364.510.318 | Neu | +100,0% | |
| Venrock Adviser, LLC | 4.148.428 | 0 | 4.148.428 | 203.480.393 | Neu | +100,0% | |
| Fairmount Funds Management LLC | 3.705.262 | 0 | 3.705.262 | 181.743.101 | Neu | +100,0% | |
| BlackRock, Inc. | 3.527.087 | 0 | 3.527.087 | 173.003.617 | Neu | +100,0% | |
| VIKING GLOBAL INVESTORS LP | 2.666.690 | 0 | 2.666.690 | 130.801.145 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 2.320.316 | 0 | 2.320.316 | 113.811.500 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 2.058.148 | 0 | 2.058.148 | 100.952.159 | Neu | +100,0% | |
| Deep Track Capital, LP | 2.034.203 | 0 | 2.034.203 | 99.777.657 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.859.631 | 0 | 1.859.631 | 91.214.901 | Neu | +100,0% | |
| STATE STREET CORP | 1.613.461 | 0 | 1.613.461 | 79.140.262 | Neu | +100,0% | |
| Remedium Capital Partners, LLC | 1.565.661 | 0 | 1.565.661 | 76.795.672 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 1.395.501 | 0 | 1.395.501 | 68.449.324 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 1.047.693 | 0 | 1.047.693 | 51.389.342 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.018.537 | 0 | 1.018.537 | 49.959.240 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1.004.056 | 0 | 1.004.056 | 49.248.948 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 954.867 | 0 | 954.867 | 46.848.119 | Neu | +100,0% | |
| MERCER GLOBAL ADVISORS INC /ADV | 802.470 | 0 | 802.470 | 39.361.154 | Neu | +100,0% | |
| Avidity Partners Management LP | 760.424 | 0 | 760.424 | 37.298.797 | Neu | +100,0% | |
| Synergy Asset Management, LLC | 356.301 | 476.196 | -119.895 | 33.909.166 | Reduziert | -25,2% | |
| Woodline Partners LP | 574.882 | 0 | 574.882 | 28.197.962 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 533.340 | 0 | 533.340 | 26.160.327 | Neu | +100,0% | |
| Bellevue Group AG | 507.008 | 0 | 507.008 | 24.868.742 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 499.673 | 0 | 499.673 | 24.508.961 | Neu | +100,0% | |
| SR ONE CAPITAL MANAGEMENT, LP | 430.330 | 0 | 430.330 | 21.107.686 | Neu | +100,0% | |
| Candriam S.C.A. | 411.006 | 0 | 411.006 | 20.159.844 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 321.949 | 0 | 321.949 | 15.791.598 | Neu | +100,0% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 313.130 | 0 | 313.130 | 15.359.027 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 299.044 | 0 | 299.044 | 14.668.109 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 246.711 | 0 | 246.711 | 12.101.175 | Neu | +100,0% | |
| Ikarian Capital, LLC | 242.021 | 0 | 242.021 | 11.871.130 | Neu | +100,0% | |
| Atika Capital Management LLC | 229.900 | 0 | 229.900 | 11.276.595 | Neu | +100,0% | |
| UBS Group AG | 212.271 | 0 | 212.271 | 10.411.892 | Neu | +100,0% | |
| Cable Car Capital, LP | 200.000 | 0 | 200.000 | 9.810.000 | Neu | +100,0% | |
| MOODY ALDRICH PARTNERS LLC | 101.411 | 135.061 | -33.650 | 9.651.285 | Reduziert | -24,9% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 190.030 | 0 | 190.030 | 9.320.972 | Neu | +100,0% | |
| Holocene Advisors, LP | 185.513 | 0 | 185.513 | 9.099.413 | Neu | +100,0% | |
| Alyeska Investment Group, L.P. | 184.863 | 0 | 184.863 | 9.067.530 | Neu | +100,0% | |
| GREAT POINT PARTNERS LLC | 183.330 | 0 | 183.330 | 8.992.337 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 176.680 | 0 | 176.680 | 8.666.154 | Neu | +100,0% | |
| MORGAN STANLEY | 175.454 | 0 | 175.454 | 8.606.019 | Neu | +100,0% | |
| PFM Health Sciences, LP | 174.052 | 0 | 174.052 | 8.537.251 | Neu | +100,0% | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 150.908 | 0 | 150.908 | 7.402.037 | Neu | +100,0% | |
| Jones Hill Capital LP | 140.843 | 0 | 140.843 | 6.908.349 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 140.789 | 0 | 140.789 | 6.905.701 | Neu | +100,0% | |
| Longaeva Partners L.P. | 136.884 | 0 | 136.884 | 6.714.160 | Neu | +100,0% | |
| Sio Capital Management, LLC | 132.496 | 0 | 132.496 | 6.498.929 | Neu | +100,0% | |
| Secure Asset Management, LLC | 65.899 | 72.422 | -6.523 | 6.271.585 | Reduziert | -9,0% | |
| KENNEDY CAPITAL MANAGEMENT LLC | 126.366 | 0 | 126.366 | 6.198.252 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 121.225 | 0 | 121.225 | 5.946.087 | Neu | +100,0% | |
| Kalehua Capital Management LLC | 118.524 | 0 | 118.524 | 5.813.602 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Synergy Asset Management, LLC | 356.301 | 476.196 | -25,2% | 33.909.166 | 53,09 | 0 % | 3 Q |
| MOODY ALDRICH PARTNERS LLC | 101.411 | 135.061 | -24,9% | 9.651.285 | 15,11 | 46 % | 3 Q |
| Secure Asset Management, LLC | 65.899 | 72.422 | -9,0% | 6.271.585 | 9,82 | 4 % | 3 Q |
| Atle Fund Management AB | 54.886 | 0 | +100,0% | 5.223.500 | 8,18 | 100 % | 1 Q |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 19.312 | 18.229 | +5,9% | 1.837.924 | 2,88 | 100 % | 4 Q |
| Police & Firemen's Retirement System of New Jersey | 14.857 | 10.207 | +45,6% | 1.413.941 | 2,21 | 100 % | 5 Q |
| AXXCESS WEALTH MANAGEMENT, LLC | 14.515 | 0 | +100,0% | 1.381.393 | 2,16 | 0 % | 1 Q |
| Brookwood Investment Group LLC | 12.990 | 15.993 | -18,8% | 1.236.258 | 1,94 | 0 % | 3 Q |
| China Universal Asset Management Co., Ltd. | 9.599 | 8.591 | +11,7% | 913.537 | 1,43 | 100 % | 7 Q |
| AlphaCentric Advisors LLC | 6.531 | 11.506 | -43,2% | 621.555 | 0,97 | 0 % | 4 Q |
| PSP Research LLC | 3.000 | 4.968 | -39,6% | 285.510 | 0,45 | 0 % | 2 Q |
| Gradient Investments LLC | 2.868 | 0 | +100,0% | 272.948 | 0,43 | 0 % | 1 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.697 | 2.525 | +6,8% | 256.673 | 0,40 | 100 % | 7 Q |
| COMMONWEALTH EQUITY SERVICES, LLC | 2.332 | 0 | +100,0% | 221.940 | 0,35 | – | 1 Q |
| Swiss Life Asset Management Ltd | 2.122 | 0 | +100,0% | 201.951 | 0,32 | 100 % | 1 Q |
| EverSource Wealth Advisors, LLC | 847 | 18 | +4605,6% | 80.608 | 0,13 | 100 % | 4 Q |
| Sterling Capital Management LLC | 177 | 1.278 | -86,2% | 16.845 | 0,03 | 0 % | 5 Q |
| Activest Wealth Management | 166 | 166 | 0,0% | 15.798 | 0,02 | 0 % | 9 Q |
| Handelsbanken Fonder AB | 160.900 | 0 | +100,0% | 15.313 | 0,02 | 0 % | 1 Q |
| GAMMA Investing LLC | 124 | 83 | +49,4% | 11.801 | 0,02 | 100 % | 3 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 31 | 0,8 | 64 |
| 31.03.2026 | ✓ | 183 | 58,5 | 2.849 |
| 31.12.2025 | ✓ | 142 | 54,7 | 36.880 |
| 30.09.2025 | ✓ | 104 | 45,8 | 17.205 |
| 30.06.2025 | ✓ | 80 | 35,2 | 9.646 |
| 31.03.2025 | ✓ | 71 | 32,7 | 8.362 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Bellevue Group AG | 507.008 | 24.868.742 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 313.130 | 15.359.027 |
| Ikarian Capital, LLC | 242.021 | 11.871.130 |
| Atika Capital Management LLC | 229.900 | 11.276.595 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 190.030 | 9.320.972 |
| Holocene Advisors, LP | 185.513 | 9.099.413 |
| JENNISON ASSOCIATES LLC | 176.680 | 8.666.154 |
| PFM Health Sciences, LP | 174.052 | 8.537.251 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 150.908 | 7.402.037 |
| Jones Hill Capital LP | 140.843 | 6.908.349 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2.320.316 | 610.000 | +35.7 % | 113.811.500 |
| CITADEL ADVISORS LLC | 1.007.537 | 281.419 | +38.8 % | 49.419.690 |
| STATE STREET CORP | 1.613.461 | 229.614 | +16.6 % | 79.140.262 |
| FMR LLC | 7.431.403 | 170.019 | +2.3 % | 364.510.318 |
| GOLDMAN SACHS GROUP INC | 246.711 | 153.716 | +165.3 % | 12.101.175 |
| Avidity Partners Management LP | 760.424 | 100.000 | +15.1 % | 37.298.797 |
| Alyeska Investment Group, L.P. | 184.863 | 84.863 | +84.9 % | 9.067.530 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 727.449 | 78.103 | +12.0 % | 35.682 |
| KENNEDY CAPITAL MANAGEMENT LLC | 126.366 | 77.680 | +159.6 % | 6.198.252 |
| Polar Capital Holdings Plc | 1.047.693 | 69.405 | +7.1 % | 51.389.342 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 499.673 | -302.669 | -37.7 % | 24.508.961 |
| Cable Car Capital, LP | 200.000 | -200.000 | -50.0 % | 9.810.000 |
| Soleus Capital Management, L.P. | 5.000 | -185.000 | -97.4 % | 245.250 |
| Deep Track Capital, LP | 2.034.203 | -127.307 | -5.9 % | 99.777.657 |
| BARCLAYS PLC | 85.737 | -87.592 | -50.5 % | 4.205.400 |
| PERCEPTIVE ADVISORS LLC | 1.395.501 | -81.000 | -5.5 % | 68.449.324 |
| UBS Group AG | 212.271 | -58.742 | -21.7 % | 10.411.892 |
| BANK OF AMERICA CORP /DE/ | 100.091 | -39.181 | -28.1 % | 4.909.463 |
| WELLS FARGO & COMPANY/MN | 14.831 | -28.430 | -65.7 % | 727.461 |
| BlackRock, Inc. | 3.527.087 | -12.328 | -0.3 % | 173.003.617 |
Zusätzlich aktuell von 109 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 02.07.2026 | Fairmount Healthcare Co-Invest III L.P. | Aktivist (13D/A) | 4,03 % | 2.573.308 | -0,38 pp | – | |
| 02.07.2026 | Kiselak Tomas | Aktivist (13D/A) | 19,47 % | 14.533.895 | Neu | – | |
| 02.07.2026 | Harwin Peter Evan | Aktivist (13D/A) | 19,50 % | 14.572.917 | -0,49 pp | – | |
| 02.07.2026 | Fairmount Healthcare Fund II L.P. | Aktivist (13D/A) | 16,03 % | 11.980.587 | -0,20 pp | – | |
| 02.07.2026 | Fairmount Funds Management LLC | Aktivist (13D/A) | 19,47 % | 14.553.895 | -0,52 pp | – | |
| 15.05.2026 | Viking Global Opportunities Parent GP LLC (+3) | Passiv (13G/A) | 5,30 % | 2.666.690 | -0,20 pp | – | |
| 15.05.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+2) | Passiv (13G/A) | 3,20 % | 1.600.014 | -0,10 pp | – | |
| 15.05.2026 | Viking Global Opportunities Drawdown Portfolio GP LLC (+2) | Passiv (13G/A) | 2,10 % | 1.066.676 | -0,10 pp | – | |
| 05.05.2026 | Harwin Peter Evan | Aktivist (13D/A) | 19,99 % | 13.660.663 | Neu | – | |
| 05.05.2026 | Fairmount Funds Management LLC (+1) | Aktivist (13D/A) | 19,99 % | 13.665.080 | 0,00 pp | – | |
| 05.05.2026 | Fairmount Healthcare Fund II L.P. | Aktivist (13D/A) | 16,23 % | 11.091.772 | +0,85 pp | – | |
| 05.05.2026 | Fairmount Healthcare Co-Invest III L.P. | Aktivist (13D/A) | 4,41 % | 2.573.308 | -0,91 pp | – | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -5,06 pp | – | |
| 17.02.2026 | RTW Investments, LP (+1) | Passiv (13G/A) | 4,30 % | 2.058.148 | Neu | – | |
| 13.02.2026 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G/A) | 3,92 % | 1.899.455 | -1,15 pp | – | |
| 13.02.2026 | Deep Track Capital, LP (+1) | Passiv (13G/A) | 4,47 % | 2.161.510 | Neu | – | |
| 13.02.2026 | Deep Track Special Opportunities Fund, LP. | Passiv (13G/A) | 0,54 % | 262.055 | Neu | – | |
| 30.01.2026 | The Vanguard Group | Passiv (13G) | 5,06 % | 2.453.530 | Neu | – | |
| 21.01.2026 | BlackRock, Inc. | Passiv (13G) | 6,60 % | 3.175.483 | +2,10 pp | – | |
| 14.11.2025 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 9,90 % | 4.909.619 | -1,20 pp | – | |
| 17.10.2025 | BlackRock, Inc. | Passiv (13G/A) | 4,50 % | 2.197.517 | -0,80 pp | – | |
| 24.09.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+2) | Passiv (13G) | 3,30 % | 1.600.014 | Neu | – | |
| 24.09.2025 | Viking Global Opportunities Drawdown Portfolio GP LLC (+2) | Passiv (13G) | 2,20 % | 1.066.676 | Neu | – | |
| 24.09.2025 | Viking Global Opportunities Parent GP LLC (+4) | Passiv (13G) | 5,50 % | 2.666.690 | Neu | – | |
| 19.09.2025 | Fairmount Funds Management LLC (+2) | Aktivist (13D/A) | 19,99 % | 11.162.741 | 0,00 pp | Item 4 of the Statement is hereby amended and supplemented as follows: Subscription Agr… | |
| 19.09.2025 | Fairmount Healthcare Fund II L.P. | Aktivist (13D/A) | 15,38 % | 8.589.433 | +1,43 pp | Item 4 of the Statement is hereby amended and supplemented as follows: Subscription Agr… | |
| 19.09.2025 | Fairmount Healthcare Co-Invest III L.P. | Aktivist (13D/A) | 5,32 % | 2.573.308 | -1,55 pp | Item 4 of the Statement is hereby amended and supplemented as follows: Subscription Agr… | |
| 17.07.2025 | BlackRock, Inc. | Passiv (13G) | 5,30 % | 1.988.880 | Neu | – | |
| 15.05.2025 | Roderick Wong, M.D. (+1) | Passiv (13G) | 5,20 % | 1.945.649 | Neu | – | |
| 13.05.2025 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G) | 5,07 % | 1.896.780 | Neu | – | |
| 10.03.2025 | Fairmount Healthcare Fund II L.P. | Aktivist (13D/A) | 13,95 % | 5.938.516 | Neu | – | |
| 10.03.2025 | Fairmount Funds Management LLC (+2) | Aktivist (13D/A) | 19,99 % | 8.511.824 | Neu | – | |
| 10.03.2025 | Fairmount Healthcare Co-Invest III L.P. | Aktivist (13D/A) | 6,87 % | 2.573.308 | Neu | – | |
| 27.02.2025 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 11,10 % | 4.148.428 | +1,11 pp | – | |
| 14.11.2024 | Janus Henderson Biotech Innovation Master Fund Ltd | Passiv (13G/A) | 0,60 % | 218.374 | -9,60 pp | – | |
| 14.11.2024 | Janus Henderson Group plc | Passiv (13G/A) | 0,70 % | 236.116 | Neu | – | |
| 14.11.2024 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 9,99 % | 3.541.941 | +4,79 pp | – | |
| 14.11.2024 | Allostery Investments GP LLC (+4) | Passiv (13G/A) | 0,30 % | 43.557 | -7,00 pp | – | |
| 14.11.2024 | Avidity Capital Partners Fund (GP) LP (+6) | Passiv (13G/A) | 2,30 % | 790.926 | -4,60 pp | – | |
| 22.10.2024 | Adage Capital Management, L.P. (+2) | Aktivist (13D/A) | 0,50 % | 175.000 | -7,78 pp | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -31.820.000 $ | – | 504.480.000 $ | 486.720.000 $ |
| 2025-12-31 | 10-K | – | -105.433.000 $ | -1,85 $ | 488.617.000 $ | 471.930.000 $ |
| 2025-09-30 | 10-Q | – | -30.277.000 $ | -0,55 $ | 509.251.000 $ | 486.791.000 $ |
| 2025-06-30 | 10-Q | – | -24.574.000 $ | -0,46 $ | 357.418.000 $ | 343.642.000 $ |
| 2025-03-31 | 10-Q | – | -20.999.000 $ | -0,40 $ | 377.112.000 $ | 364.725.000 $ |
| 2024-12-31 | 10-K | – | -83.724.000 $ | -3,87 $ | 396.019.000 $ | 382.221.000 $ |
| 2024-09-30 | 10-Q | – | -28.623.000 $ | -1,46 $ | 414.090.000 $ | 342.368.000 $ |
| 2024-06-30 | 10-Q | – | -22.243.000 $ | -6,96 $ | 33.844.000 $ | -28.981.000 $ |
| 2024-03-31 | 10-Q | 0 $ | -2.009.000 $ | -0,14 $ | 36.706.000 $ | -7.059.000 $ |
| 2023-12-31 | 10-K | 0 $ | -5.339.000 $ | -0,37 $ | 37.861.000 $ | 37.020.000 $ |
| 2023-12-31 | 10-Q | – | -1.089.000 $ | – | 37.861.000 $ | 37.020.000 $ |
| 2023-09-30 | 10-Q | – | -1.424.000 $ | -0,10 $ | 39.184.000 $ | 37.968.000 $ |
| 2023-06-30 | 10-Q | – | -1.480.000 $ | -0,10 $ | 41.083.000 $ | 39.238.000 $ |
| 2023-03-31 | 10-Q | 0 $ | -1.346.000 $ | -0,09 $ | 42.059.000 $ | 40.531.000 $ |
| 2022-12-31 | 10-K | 0 $ | -9.926.000 $ | -0,69 $ | 43.085.000 $ | 41.673.000 $ |
| 2022-12-31 | 10-Q | – | -1.174.000 $ | – | 43.085.000 $ | 41.673.000 $ |
| 2022-09-30 | 10-Q | – | -2.333.000 $ | -0,16 $ | 44.965.000 $ | 42.727.000 $ |
| 2022-06-30 | 10-Q | – | -3.147.000 $ | -0,22 $ | 48.101.000 $ | 44.963.000 $ |
| 2022-03-31 | 10-Q | 0 $ | -3.272.000 $ | -0,23 $ | 51.014.000 $ | 47.938.000 $ |
| 2021-12-31 | 10-K | 0 $ | -19.322.000 $ | -1,39 $ | 54.924.000 $ | 51.043.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q2 2025 | 30.06.2025 | 11.08.2025 | – | -0,46 |
| Q1 2025 | 31.03.2025 | 14.05.2025 | – | -0,40 |
| Q3 2024 | 30.09.2024 | 13.11.2024 | – | -1,46 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | – | -6,96 |
| Q1 2024 | 31.03.2024 | 25.04.2024 | 0 USD | -0,14 |
| Q3 2023 | 30.09.2023 | 18.10.2023 | – | -0,10 |
| Q2 2023 | 30.06.2023 | 21.07.2023 | – | -0,10 |
| Q1 2023 | 31.03.2023 | 24.04.2023 | 0 USD | -0,09 |
| Q3 2022 | 30.09.2022 | 28.10.2022 | – | -0,16 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 13.05.2026 | 10-Q | 31.03.2026 | 43 Tage | SEC » |
| 12.03.2026 | 10-K | 31.12.2025 | 71 Tage | SEC » |
| 12.11.2025 | 10-Q | 30.09.2025 | 43 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 14.05.2025 | 10-Q | 31.03.2025 | 44 Tage | SEC » |
| 06.03.2025 | 10-K | 31.12.2024 | 65 Tage | SEC » |
| 13.11.2024 | 10-Q | 30.09.2024 | 44 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 25.04.2024 | 10-Q | 31.03.2024 | 25 Tage | SEC » |
| 01.02.2024 | 10-K | 31.12.2023 | 32 Tage | SEC » |
| 18.10.2023 | 10-Q | 30.09.2023 | 18 Tage | SEC » |
| 21.07.2023 | 10-Q | 30.06.2023 | 21 Tage | SEC » |
| 24.04.2023 | 10-Q | 31.03.2023 | 24 Tage | SEC » |
| 24.02.2023 | 10-K | 31.12.2022 | 55 Tage | SEC » |
| 28.10.2022 | 10-Q | 30.09.2022 | 28 Tage | SEC » |
| 02.08.2022 | 10-Q | 30.06.2022 | 33 Tage | SEC » |
| 02.05.2022 | 10-Q | 31.03.2022 | 32 Tage | SEC » |
| 14.03.2022 | 10-K | 31.12.2021 | 73 Tage | SEC » |
| 02.11.2021 | 10-Q | 30.09.2021 | 33 Tage | SEC » |
| 04.08.2021 | 10-Q | 30.06.2021 | 35 Tage | SEC » |
| 11.05.2021 | 10-Q | 31.03.2021 | 41 Tage | SEC » |
| 18.03.2021 | 10-K | 31.12.2020 | 77 Tage | SEC » |
| 02.11.2020 | 10-Q | 30.09.2020 | 33 Tage | SEC » |
| 05.08.2020 | 10-Q | 30.06.2020 | 36 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 29.04.2026 | Kapitalerhöhung | $700,4 Mio · $72,50/Aktie | SEC » |
| 27.04.2026 | Kapitalerhöhung | $500,0 Mio | SEC » |
| 27.04.2026 | Kapitalerhöhung | – | SEC » |
| 05.11.2025 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 18.03.2022 | Kapitalerhöhung | $11,2 Mio | SEC » |
| 06.04.2021 | Kapitalerhöhung | $50,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 17.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 17.04.2026 | HV-Einladung | 02.06.2026 Jahres-HV | 07.04.2026 | DEF 14A | SEC » |
| 18.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 18.04.2025 | HV-Einladung | 02.06.2025 Jahres-HV | 07.04.2025 | DEF 14A | SEC » |
| 18.10.2024 | HV-Einladung | 14.11.2024 a.o. HV | 16.10.2024 | DEF 14A | SEC » |
| 07.10.2024 | Vorläufig | — | — | PRE 14A | SEC » |
| 19.12.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 19.12.2023 | HV-Einladung | 30.01.2024 Jahres-HV | 06.12.2023 | DEF 14A | SEC » |
| 03.11.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 03.11.2022 | HV-Einladung | 15.12.2022 Jahres-HV | 25.10.2022 | DEF 14A | SEC » |
| 28.06.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 21.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 21.04.2021 | HV-Einladung | 10.06.2021 Jahres-HV | 09.04.2021 | DEF 14A | SEC » |
| 09.12.2020 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.10.2020 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.10.2020 | HV-Einladung | 10.12.2020 Jahres-HV | 14.10.2020 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 27.08.2024 | Fusion | 425 | Ziel: Oruka Therapeutics, Inc. | SEC » |
| 16.08.2024 | Fusion | 425 | Ziel: ARCA biopharma, Inc. | SEC » |
| 15.08.2024 | Fusion | 425 | Ziel: Genvara Biopharma, Inc. · $300.000,00 Cash | SEC » |
| 09.08.2024 | Fusion | 425 | Ziel: Oruka Therapeutics, Inc | SEC » |
| 01.08.2024 | Fusion | 425 | – | SEC » |
| 22.07.2024 | Fusion | S-4/A | Ziel: ORUKA · Umtausch 6,8699 Akt./Ziel-Aktie | SEC » |
| 09.07.2024 | Fusion | S-4/A | Ziel: ORUKA · Umtausch 7,4631 Akt./Ziel-Aktie | SEC » |
| 09.07.2024 | Fusion | 425 | Ziel: Oruka Therapeutics, Inc. | SEC » |
| 18.06.2024 | Fusion | S-4/A | Ziel: Oruka · Umtausch 7,4631 Akt./Ziel-Aktie | SEC » |
| 06.06.2024 | Fusion | 425 | Ziel: ARCA biopharma, Inc. | SEC » |
| 14.05.2024 | Fusion | S-4 | Ziel: ORUKA · Umtausch 7,4631 Akt./Ziel-Aktie | SEC » |
| 25.04.2024 | Fusion | 425 | – | SEC » |
| 03.04.2024 | Fusion | 425 | Ziel: Oruka · Aktientausch · Umtausch 0,9762 Akt./Ziel-Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 01.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Officers The information set forth in Item 5.02 of this Current Report on Form 8-K under the heading “Appointment of… |
| 23.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 04.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 06.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 31.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 04.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 13.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 19.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 09.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02(e) On October 23, 2020, the Board of Directors (the “Board”) of ARCA biopharma, Inc., a Delaware corporation… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 01.06.2026 | Wesentliche Vereinbarung | 0,45 | 58 | Oruka Therapeutics erweitert die IL-23-Lizenzvereinbarung mit Paragon Therapeutics und dehnt das Geschäftsfeld auf inflammatory bowel diseas… 🔒 | SEC |
| 30.04.2026 | Wesentliche Vereinbarung | -0,05 | 45 | Oruka Therapeutics kündigte ein Underwriting Agreement für die Ausgabe von 9,66 Millionen Stammaktien an und verfügt über Barbestände von et… 🔒 | SEC |
| 27.04.2026 | Sonstiges | 0,40 | 65 | Oruka Therapeutics kündigte Ergebnisse der Phase-2a EVERLAST-A-Studie seines Anti-IL-23-Antikörpers ORKA-001 bei mittelschwerer bis schwerer… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 3.417 | 92,49 | 316.038 |
| 2026-06-29 | 300.808 | 90,60 | 27.253.205 |
| 2026-06-26 | 138.660 | 86,63 | 12.012.116 |
| 2026-06-23 | 20.781 | 85,38 | 1.774.282 |
| 2026-06-22 | 21.546 | 72,34 | 1.558.638 |
| 2026-06-17 | 30.923 | 67,71 | 2.093.796 |
| 2026-06-16 | 25.864 | 68,86 | 1.780.995 |
| 2026-06-15 | 55.720 | 69,89 | 3.894.271 |
| 2026-06-12 | 62.805 | 68,47 | 4.300.258 |
| 2026-06-11 | 57.427 | 64,03 | 3.677.051 |
| 2026-06-10 | 61.710 | 66,93 | 4.130.250 |
| 2026-06-09 | 82.632 | 64,06 | 5.293.406 |
| 2026-06-08 | 75.479 | 60,14 | 4.539.307 |
| 2026-06-05 | 70.818 | 62,28 | 4.410.545 |
| 2026-06-04 | 71.118 | 57,20 | 4.067.950 |
| 2026-06-03 | 58.227 | 55,23 | 3.215.877 |
| 2026-06-02 | 45.965 | 55,01 | 2.528.535 |
| 2026-06-01 | 18.017 | 58,53 | 1.054.535 |
| 2026-05-29 | 393 | 57,98 | 22.786 |
| 2026-05-28 | 5.495 | 57,99 | 318.655 |
| 2026-05-26 | 4.059 | 60,61 | 246.016 |
| 2026-05-22 | 86.945 | 58,69 | 5.102.802 |
| 2026-05-19 | 189 | 58,34 | 11.026 |
| 2026-05-18 | 222.058 | 61,93 | 13.752.052 |
| 2026-05-15 | 274.258 | 63,90 | 17.525.086 |
| 2026-05-14 | 274.099 | 63,18 | 17.317.575 |
| 2026-05-13 | 290.428 | 64,65 | 18.776.170 |
| 2026-05-12 | 292.473 | 65,68 | 19.209.627 |
| 2026-05-11 | 291.322 | 64,59 | 18.816.488 |
| 2026-05-08 | 251.644 | 64,07 | 16.122.831 |
| 2026-05-07 | 537.968 | 69,79 | 37.544.787 |
| 2026-05-06 | 276.803 | 68,95 | 19.085.567 |
| 2026-05-05 | 14.461 | 66,46 | 961.078 |
| 2026-05-04 | 19.416 | 62,58 | 1.215.053 |
| 2026-05-01 | 107.964 | 68,41 | 7.385.817 |
| 2026-04-30 | 23.562 | 68,10 | 1.604.572 |
| 2026-04-29 | 28.928 | 73,99 | 2.140.383 |
| 2026-04-28 | 33.013 | 76,39 | 2.521.863 |
| 2026-04-27 | 33.205 | 69,03 | 2.292.141 |
| 2026-04-24 | 40.322 | 67,74 | 2.731.412 |
| 2026-04-23 | 52.332 | 69,68 | 3.646.494 |
| 2026-04-22 | 71.741 | 69,00 | 4.950.129 |
| 2026-04-21 | 73.506 | 68,87 | 5.062.358 |
| 2026-04-20 | 74.254 | 68,92 | 5.117.586 |
| 2026-04-17 | 74.284 | 67,07 | 4.982.228 |
| 2026-04-16 | 41.049 | 65,55 | 2.690.762 |
| 2026-03-26 | 21.885 | 43,81 | 958.782 |
| 2026-03-20 | 58 | 38,82 | 2.252 |
| 2026-03-17 | 1.104 | 41,75 | 46.092 |
| 2026-03-16 | 19.053 | 40,00 | 762.120 |
| 2026-03-06 | 27.345 | 33,17 | 907.034 |
| 2026-03-02 | 97 | 34,41 | 3.338 |
| 2026-02-23 | 2.000 | 32,34 | 64.680 |